Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Patients and data tracking

- PMLiVE

Alexion convinces NICE of Soliris’ value

But recommendation of the expensive 'ultra orphan' drug' comes with conditions

- PMLiVE

Amgen submits melanoma and cholesterol drugs to EMA

Regulator will assess talimogene laherparepvec and evolocumab

- PMLiVE

Novo Nordisk gives up on inflammation R&D

Follows disappointing trial results for arthritis drug

- PMLiVE

Teva stakes its claim to the asthma antibody market

Plans to file reslizumab early next year

- PMLiVE

New eye indication for Allergan’s Ozurdex

EU approval extends the drug's use to diabetic macular oedema

- PMLiVE

BMS launches hepatitis C pill Daklinza in the UK

Will be offered as a combination treatment with Gilead's Solvadi

- PMLiVE

Fishawack opens San Francisco office

Comms agency's new premises will serve its growing west coast client base

- PMLiVE

EMA names head of comms team

Marie-Agnes Heine joins regulator from World Health Organization

- PMLiVE

Genzyme continues MS drug rollout across EU

Lemtrada and Aubagio now available in Republic of Ireland

- PMLiVE

Exelixis axes staff as lead cancer programme fails

Plans to cut workforce by 70% after cabozantinib disappoints in phase III

- PMLiVE

Novo Nordisk debuts diabetes combo in Mexico

Requires fewer daily injections than current insulin treatment

- PMLiVE

Germany’s IQWiG denies Astellas’ incontinence drug

But Janssen receives recommendation for hepatitis C treatment Olysio

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links